alexa Chickenpox | Sweden | PDF | PPT| Case Reports | Symptoms | Treatment

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Relevant Topics

Chickenpox

  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
  • Chickenpox

    Chicken Pox
    Chickenpox is a highly contagious viral infection in which a person develops extremely itchy blisters all over the body and it is common childhood disease caused by a virus in the herpes family of viruses called the varicella virus. The varicella virus can remain in the body for decades and become active again in adults, causing herpes zoster (shingles). Shingles involves the occurrence of painful skin sores along the distribution of nerves across the trunk or face.

  • Chickenpox

    Symptoms
    Itchy blisters on a red base, progressing to scabs, appear along with newer blisters, mainly on the trunk, face, and scalp and last 5 to 10 days. Other symptoms include fever, headache, tiredness and loss of appetite.
    The chickenpox rash occurs about 10 to 21 days after coming into contact with someone who had the disease. The average child develops 250 to 500 small, itchy, fluid-filled blisters over red spots on the skin.

  • Chickenpox

    Therapeutic aspects
    There are several things that can be done at home to help relieve the symptoms and prevent skin infections. Calamine lotion and colloidal oatmeal baths may help relieve some of the itching. Keeping fingernails trimmed short may help prevent skin infections caused by scratching blisters.

  • Chickenpox

    Statistics
    Yes. Between March 1995 and July 1998, the federal Vaccine Adverse Events Reporting System (VAERS) received 6, 574 reports of health problems after chickenpox vaccination. That translates into 67.5 adverse events per 100,000 doses of vaccine or one in 1,481 vaccinations. About four percent of cases (about 1 in 33,000 doses) were serious including shock, encephalitis, thrombocytopenia (blood disorder) and 14 deaths. The VAERS data has led to the addition of 17 adverse events to the manufacturer's product label since the vaccine was licensed in 1995, including secondary bacterial infections (cellulitis), secondary transmission of vaccine virus infection to close contacts, transverse myelitis and Guillain Barre syndrome (brain disorders) and herpes zoster (shingles).

 

High Impact List of Articles

Conference Proceedings